Funded Biotechnology Startups in Austria
Disclosed deal sizes in this Austria biotechnology slice are highly uneven: the largest disclosed round is Hookipa Pharma’s $21M on 2023-12-21, and it sits…
Disclosed deal sizes in this Austria biotechnology slice are highly uneven: the largest disclosed round is Hookipa Pharma’s $21M on 2023-12-21, and it sits well above the rest of the disclosed amounts (notably Graph Therapeutics at $5M on 2026-06-22 and Sarcura/Arkeon Biotechnologies at $7M on 2022-11-17 and 2022-03-07). Stage and disclosure also cluster: 5 of 12 entries show “Series Unknown” (VALANX Biotech, Brightmind.ai, invIOs, Briefcase Biotec, Hookipa Pharma), while 2 of 12 are “undisclosed” (Innovacell and invIOs), making disclosed sizing and stage signals incomplete for several companies. Geography concentrates in specific Austrian cities, with Vienna appearing repeatedly (Brightmind.ai 2024-05-08 at $800K; Hookipa Pharma 2023-12-21 at $21M; invIOs 2023-09-05 as undisclosed). Temporally, the 12 rows span 2022-02-10 (Celeris Therapeutics) through 2026-06-22 (Graph Therapeutics), and the most recent year includes three disclosed rounds (Graph Therapeutics $5M on 2026-06-22, VALANX Biotech $4M on 2026-03-12, aTension.life $3M on 2025-04-10).
Most recent rounds
12 shownRelated listings
Frequently asked
What’s the largest disclosed round here, and how separated is it from other disclosed amounts?
Hookipa Pharma’s $21M (2023-12-21) is the only disclosed figure above the rest’s mid-single-digit to low-teens range; the next-largest disclosed rounds are $7M (Sarcura on 2022-11-17 and Arkeon Biotechnologies on 2022-03-07) and $5M (Graph Therapeutics on 2026-06-22).
Do the most recent rounds cluster in a narrow window or come from earlier years as well?
Yes for recent activity: three disclosed rounds fall within roughly the last 12–18 months of the list’s range—Graph Therapeutics at $5M (2026-06-22), VALANX Biotech at $4M (2026-03-12), and aTension.life at $3M (2025-04-10). The oldest disclosed dates shown are Celeris Therapeutics on 2022-02-10 and $2M at Lignovations on 2023-12-04, indicating spread beyond the newest cluster.
Which cities show up repeatedly for Austrian biotech funding in these 12 rows?
Vienna is the most frequent city, appearing with Brightmind.ai ($800K on 2024-05-08), Hookipa Pharma ($21M on 2023-12-21), and invIOs (undisclosed on 2023-09-05). Klosterneuburg/Niederosterreich also recurs via Graph Therapeutics (2026-06-22, $5M), plus Sarcura (2022-11-17, $7M), suggesting a second regional concentration.
How complete are stage signals—what fraction is “Series Unknown” or “undisclosed” in this list?
Stage classification is missing or unclear for a majority: 5 of 12 entries list “Series Unknown” (VALANX Biotech, Brightmind.ai, Hookipa Pharma, invIOs, Briefcase Biotec). Separately, 2 of 12 entries are “undisclosed” (Innovacell on 2025-08-21 and invIOs on 2023-09-05), so disclosed sizing and stage both don’t fully align across the dataset.
Are there stage-led clusters (e.g., Seed) that dominate across years?
Seed appears frequently across different years, including Sarcura ($7M on 2022-11-17), Arkeon Biotechnologies ($7M on 2022-03-07), and Lignovations ($2M on 2023-12-04), as well as later entries like Graph Therapeutics is Seed on 2026-06-22 and aTension.life is Seed on 2025-04-10. Earlier and later Seed rounds both show up, with no single year owning the stage entirely.
Which entry is a clear sizing outlier among disclosed rounds, and where does it sit in time?
Hookipa Pharma at $21M (2023-12-21) is the clear disclosed-size outlier, and it is roughly centered between the 2022 Seed rounds (e.g., Arkeon Biotechnologies $7M on 2022-03-07; Sarcura $7M on 2022-11-17) and the newer 2024–2026 entries such as Graph Therapeutics ($5M on 2026-06-22) and Brightmind.ai ($800K on 2024-05-08).
Know which startups just got funded. Every week.
Fresh funding rounds, new companies, and the sectors moving fastest — in your inbox every Monday morning.
Free. Sent every Monday. Unsubscribe anytime.